Free shipping on all orders over $ 500

Vorasidenib

Cat. No. M10308

All AbMole products are for research use only, cannot be used for human consumption.

Vorasidenib Structure
Synonym:

AG-881

Size Price Availability Quantity
10mM*500uL in DMSO USD 79 In stock
1mg USD 48 In stock
2mg USD 75 In stock
5mg USD 130 In stock
10mg USD 210 In stock
50mg USD 570 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vorasidenib (AG-881) is a potent and selective, first-in-Class, brain-penetrant orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. In a TS603-IDH1R132H mouse xenograft model, Vorsidenib reduces tumor growth at a dose of 50 mg/kg.

Chemical Information
Molecular Weight 414.74
Formula C14H13ClF6N6
CAS Number 1644545-52-7
Solubility (25°C) DMSO 85 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Ingo K Mellinghoff, et al. Clin Cancer Res. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

[2] Preantha Poonan, et al. Chem Biodivers. Dual-Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib

[3] Zenon Konteatis, et al. ACS Med Chem Lett. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

[4] Jiao Chen, et al. Mini Rev Med Chem. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors

Related Isocitrate Dehydrogenase (IDH) Products
AGI-5198

AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 μM and 0.16 μM, respectively.

AGI-6780

AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.

Enasidenib

Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.

BAY-1436032

BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells.

GSK864

GSK864 is a cell penetrant, potent and selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) that potently inhibits intracellular 2-hydroxyglutarate (2-HG) production in HT-1080 cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vorasidenib, AG-881 supplier, Isocitrate Dehydrogenase (IDH), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.